Do COMT rs4680 AG, CYP1A2 rs762551 AC, and NPSR1 rs324981 AT alter catecholamine methylation, caffeine clearance, and arousal signaling?

Clinical and physiological evidence

Robust genetic and pharmacokinetic evidence validates how specific genetic variations alter neurotransmitter clearance, drug metabolism, and central nervous system arousal:

• COMT rs4680 (Val158Met): This G-to-A substitution alters the thermostability of the catechol-O-methyltransferase enzyme. Individuals with the heterozygous AG (Val/Met) genotype exhibit a co-dominant, intermediate phenotype. They experience a roughly 40% to 50% reduction in enzymatic activity compared to high-activity GG (Val/Val) homozygotes, leading to a diminished clearance rate of dopamine and noradrenaline.
• CYP1A2 rs762551 (CYP1A2*1F): This polymorphism in intron 1 dictates the inducibility of the primary enzyme responsible for caffeine metabolism. While homozygous AA individuals are "rapid" metabolizers, those with the heterozygous AC genotype have reduced enzyme activity. This slower clearance translates to a prolonged caffeine half-life and higher post-dose plasma levels, making carriers more sensitive to sustained cardiovascular and sleep-disrupting effects.
• NPSR1 rs324981 (Asn107Ile): The T (Ile107) allele is a functional gain-of-function variant. Heterozygous AT carriers exhibit hyperactive receptor profiles, showing significantly increased sensitivity to neuropeptide S (NPS) compared to wild-type AA homozygotes.

Mechanistic explanations

The physiological consequences of these genetic profiles are driven by distinct molecular pathways:

• Catecholamine clearance: The reduced catalytic efficiency of the COMT AG genotype directly limits the methylation and subsequent inactivation of synaptic catecholamines in the prefrontal cortex, prolonging dopaminergic and noradrenergic signaling.
• Xenobiotic metabolism: The C allele of CYP1A2 rs762551 impairs the transcriptional inducibility of the cytochrome P450 1A2 enzyme, slowing down the primary demethylation pathway that converts caffeine into paraxanthine.
• Arousal pathways: The NPSR1 T allele increases downstream receptor potency in response to NPS by approximately 10-fold. Because the NPS/NPSR1 system regulates sleep-wake transitions and stress responses, this hyperactive signaling triggers elevated autonomic reactivity, hyperreactive amygdala activation, and altered fronto-limbic processing under acute stress.

Clinical implications

• Sleep and anxiety vulnerability: The hyperarousal state associated with the NPSR1 AT genotype directly predisposes individuals to sleep architecture disruptions, prolonged sleep latency, and primary insomnia. It also lowers the threshold for autonomic stress responses, increasing vulnerability to panic disorder and heightened anxiety sensitivity.
• Synergistic caffeine sensitivity: Because the CYP1A2 AC genotype slows caffeine clearance and the NPSR1 AT genotype increases baseline arousal sensitivity, carriers of both variants are highly susceptible to prolonged, caffeine-induced sleep disruption and anxiety.

Bottom line

The claim is fully supported. The COMT rs4680 AG genotype reduces catecholamine methylation by 40% to 50% compared to GG; the CYP1A2 rs762551 AC genotype impairs caffeine clearance compared to AA; and the NPSR1 rs324981 AT genotype represents a functional gain-of-function that increases vulnerability to persistent arousal, sleep disruptions, and anxiety.